Table 1.
Baseline Characteristics of the Patient Cohort: Regular Statin Users, Irregular Users, and Nonusers
| Valid Cases | All | Statin Users | Irregular Users | Nonusers | P Value | |
|---|---|---|---|---|---|---|
| Patients, n (%) | 1945 | 1945 | 1200 (61.7) | 651 (33.5) | 94 (4.8) | |
| Age, y, mean ± SD | 1945 | 65.6 ± 11.8 | 65.2 ± 11.7 | 66.1 ± 11.6 | 68.4 ± 13.3 | 0.011 |
| Female sex | 1945 | 30.1 | 29.9 | 30.3 | 31.9 | 0.684 |
| BMI, mean ± SD | 1929 | 27.5 ± 4.8 | 27.4 ± 4.8 | 27.6 ± 4.8 | 27.1 ± 4.7 | 0.614 |
| Cholesterol levels at admission (mmol/L) | ||||||
| fP‐Cholesterol, mean ± SD | 1608 | 4.33 ± 1.09 | 4.35 ± 1.09 | 4.32 ± 1.10 | 4.16 ± 0.99 | 0.332 |
| fP‐LDL‐C, mean ± SD | 1543 | 2.40 ± 0.89 | 2.42 ± 0.89 | 2.40 ± 0.91 | 2.29 ± 0.82 | 0.475 |
| fP‐HDL‐C, mean ± SD | 1608 | 1.24 ± 0.36 | 1.24 ± 0.35 | 1.24 ± 0.39 | 1.22 ± 0.38 | 0.892 |
| Risk factors and prior procedures | ||||||
| Smoker | 1928 | 31.6 | 30.8 | 34.5 | 23.1 | 0.098 |
| Ex‐smoker | 1928 | 32.2 | 31.7 | 32.2 | 32.4 | 0.365 |
| Hypertension | 1945 | 65.6 | 64.4 | 68.2 | 61.7 | 0.607 |
| DM | 1945 | 22.8 | 19.8 | 27.8 | 26.6 | 0.034 |
| Dyslipidemia | 1945 | 71.1 | 70.2 | 75.1 | 54.3 | 0.002 |
| Prior MI | 1926 | 20.4 | 18.6 | 24.3 | 21.5 | 0.050 |
| Prior PCI | 1945 | 11.5 | 11.0 | 12.4 | 10.6 | 0.869 |
| Prior CABG | 1945 | 9.6 | 9.2 | 10.4 | 9.6 | 0.903 |
| Vessel status | ||||||
| 1‐artery disease | 1945 | 41.1 | 42.2 | 38.1 | 47.9 | 0.861 |
| 2‐artery disease | 1945 | 26.1 | 25.8 | 26.4 | 26.6 | 0.861 |
| 3‐artery disease | 1945 | 32.4 | 31.8 | 34.7 | 25.5 | 0.861 |
| ACS type | ||||||
| UA | 1945 | 11.0 | 11.6 | 10.0 | 10.6 | 0.474 |
| NSTEMI | 1945 | 54.3 | 52.9 | 56.2 | 58.5 | 0.474 |
| STEMI | 1945 | 34.7 | 35.5 | 33.8 | 30.9 | 0.474 |
| Procedures during this care period or later | ||||||
| PCI | 1945 | 71.0 | 72.2 | 68.5 | 73.4 | 0.872 |
| CABG | 1945 | 14.0 | 14.4 | 14.3 | 6.4 | 0.027 |
| Comorbidities | ||||||
| Arrhythmias | 1929 | 16.7 | 16.0 | 17.4 | 21.3 | 0.072 |
| Cancer | 1943 | 7.1 | 6.3 | 8.4 | 8.5 | 0.120 |
| Kidney disease | 1945 | 2.4 | 2.2 | 2.8 | 2.1 | 0.859 |
| Rheumatoid arthritis | 1944 | 4.6 | 4.8 | 4.1 | 4.3 | 0.636 |
| Psychiatric disorder | 1945 | 2.4 | 2.9 | 3.4 | 3.2 | 0.418 |
| CVA | 1920 | 11.9 | 10.1 | 15.6 | 8.7 | 0.002 |
| PVD | 1921 | 9.2 | 9.1 | 9.5 | 8.7 | 0.954 |
| Concurrent drugs | ||||||
| β‐Blockers | 1942 | 92.6 | 91.3 | 92.2 | 90.4 | 0.536 |
| ASA | 1945 | 91.4 | 93.2 | 91.7 | 91.5 | 0.761 |
| ACE inhibitors | 1939 | 57.7 | 59.0 | 56.1 | 57.0 | 0.523 |
| ATR blockers | 1939 | 15.1 | 14.5 | 16.5 | 13.5 | 0.489 |
| Clopidogrel | 1943 | 79.7 | 79.6 | 80.0 | 79.6 | 0.858 |
| Ca blockers | 1935 | 12.9 | 11.7 | 15.5 | 10.6 | 0.054 |
Abbreviations: ACE, angiotensin‐converting enzyme; ACS, acute coronary syndrome; ASA, acetylsalicylic acid; ATR, angiotensin receptor; BMI, body mass index; Ca, calcium; CABG, coronary artery bypass graft; CV, cardiovascular; CVA, cerebrovascular attack; DM, diabetes mellitus; HDL‐C, high‐density lipoprotein cholesterol; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; NSTEMI, non–ST‐elevation myocardial infarction; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; SD, standard deviation; STEMI, ST‐elevation myocardial infarction; UA, unstable angina.